Article
KIT mutations in GIST.
Current opinion in genetics & development - 1 Feb 2007
Fletcher Jonathan A, Rubin Brian P
Abstract excerpt
Most gastrointestinal stromal tumors (GISTs) contain oncogenic KIT or PDGFRA receptor tyrosine kinase mutations. These rare neoplasms are remarkably sensitive to the KIT and PDGFRA kinase inhibitors imatinib (also known as Gleevec) and sunitinib (Sutent), which have recently been approved as the standard therapeutic courses for patients with inoperable GIST. However, most GIST patients eventually develop clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.